Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Neurocrine Biosciences, Inc. NBIX
$96.56
-$1.24 (-1.29%)
На 18:00, 12 мая 2023
+26.21%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
9465243474.00000000
-
week52high
129.29
-
week52low
80.50
-
Revenue
1488700000
-
P/E TTM
61
-
Beta
0.48788900
-
EPS
1.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Neutral | Neutral | 08 авг 2022 г. |
| Barclays | Overweight | Overweight | 05 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| Barclays | Overweight | Overweight | 12 апр 2022 г. |
| JP Morgan | Overweight | Overweight | 04 апр 2022 г. |
| Wells Fargo | Equal-Weight | 26 сент 2022 г. | |
| UBS | Buy | 11 окт 2022 г. | |
| Citigroup | Buy | Buy | 24 окт 2022 г. |
| Mizuho | Neutral | Neutral | 20 окт 2022 г. |
| Raymond James | Outperform | Outperform | 03 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 03 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 02 ноя 2022 г. |
| Mizuho | Neutral | Neutral | 02 ноя 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ROBERTS EIRY | D | 26171 | 1457 | 31 янв 2023 г. |
| Lloyd-Smith Malcolm | D | 28582 | 1666 | 31 янв 2023 г. |
| Onyia Jude | D | 2477 | 126 | 31 янв 2023 г. |
| GORMAN KEVIN CHARLES | D | 465278 | 2707 | 31 янв 2023 г. |
| Lippoldt Darin | D | 30357 | 1250 | 31 янв 2023 г. |
| Gano Kyle | D | 112820 | 1541 | 31 янв 2023 г. |
| Boyer David W. | D | 3911 | 1104 | 31 янв 2023 г. |
| Cooke Julie | D | 15926 | 916 | 31 янв 2023 г. |
| BENEVICH ERIC | D | 16729 | 1207 | 31 янв 2023 г. |
| ABERNETHY MATT | D | 21357 | 1283 | 31 янв 2023 г. |
Новостная лента
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch
Seeking Alpha
24 апр 2023 г. в 19:30
Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch.
3 Pharma Stocks That Could See a Surge in Demand in 2023
InvestorPlace
24 апр 2023 г. в 15:55
As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector's positive momentum.
Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect
Seeking Alpha
22 апр 2023 г. в 09:32
Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect.
3 Growth Stocks That Could Disrupt the Healthcare Industry
InvestorPlace
13 мар 2023 г. в 15:29
Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.
Neurocrine Biosciences to Participate at Investor Conferences in March
PRNewsWire
08 мар 2023 г. в 16:01
Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN DIEGO , March 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m.